Denosumab biosimilar (AryoGen)

地舒单抗生物类似药 (AryoGen)

Report date: 2024/11/09 20:00:08

Base Information

Drug NameDenosumab biosimilar (AryoGen)
Drug Alias NameDyenix德尼单抗生物仿制药 (AryoGen)地舒单抗生物仿制药 (AryoGen)迪诺舒单抗生物仿制药 (AryoGen)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionTumor necrosis factor ligand superfamily member 11 inhibitors
TargetsTumor necrosis factor ligand superfamily member 11
Therapy Area/IndicationsOsteoporosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIran
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAryogen Biopharma
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAryogen Pharmed CoPetrovax Pharma
Active IndicationsN/A
Inactive IndicationsOsteoporosis

Other Information

ATC CodeM05BX04
Related LinksN/A